Lupus-nephritis treatment pipeline remains highly active

Advancing programs include dapirolizumab pegol, enpatoran, litifilimab, nipocalimab, orelabrutinib, telitacicept, belimumab optimization, emerging dapagliflozin data, and broader-SLE candidate iptocigistat. B-cell-directed approaches such as obinutuzumab and CAR-T remain prominent, while a reported phase 3 telitacicept signal combines improved clinical response with more adverse events; detailed results are needed before judging significance.